MedicineMedicine
Schedule H (Prescription Required)Vaccines & ImmunoglobulinsCode: 1660

Human Normal Immunoglobulin (IM) 16.5% Injection

Generic Formulation:Human Normal Immunoglobulin IP 16.5% (For IM use)
Pack Size:2 ml vial
Common Commercial Brand Equivalents:Market reference only

MRP Under Process

Official PMBI MRP is being updated for catalog code 1660.

Locate Jan Aushadhi Kendra
Clinical InformationReport Error

Clinical Overview

Human Normal Immunoglobulin (IVIG / IM) is a sterile solution of concentrated human polyvalent immunoglobulin G (IgG) containing antibodies against a wide spectrum of infectious pathogens, prepared from pooled human plasma of thousands of healthy donors. Provides immediate passive antibody immunity and potent immunomodulation. Indicated for primary immunodeficiency syndromes, idiopathic thrombocytopenic purpura (ITP), Guillain-Barré syndrome, Kawasaki disease, and passive prophylaxis against hepatitis A or measles.

Active Pharmaceutical Ingredients

AI-assistedClinical summary synthesized from pharmacopoeial references (CDSCO, WHO EML, IP/BP/USP). Not clinician-reviewed. Drug code 1660.Report inaccuracy

Usage Guidelines

Administered strictly in specialized clinical or hospital settings. IV formulations are infused slowly starting at a low rate (e.g. 0.5-1 mL/kg/hr) and titrated gradually under continuous monitoring of vital signs. IM formulations are injected deep into large muscle masses.

General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.

Possible Side Effects

Common: Headache, chills, fever, flushing, nausea, backache, fatigue during infusion. Rare/Severe: Anaphylaxis (especially in IgA-deficient individuals), aseptic meningitis syndrome, acute renal failure (osmotic nephrosis associated with sucrose stabilizers), thrombosis/stroke, and transfusion-related acute lung injury (TRALI).

*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.

Precautions & Warnings

Contraindicated in patients with selective IgA deficiency who possess anti-IgA antibodies (high risk of fatal anaphylaxis). Ensure adequate hydration before infusion. Monitor renal function and hydration, particularly in elderly or diabetic patients.

Schedule H (Prescription Required)

This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.

Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.